Barinthus Biotherapeuticsformerly known as Vaccitech, is receiving a funding injection of $34.8 million (€31.6 million) to develop a vaccine against Middle East Respiratory Syndrome (MERS), caused by MERS-CoV. The investment from the Coalition for Epidemic Preparedness Innovations will be used to accelerate the development of this vaccine.
Specifically, Barinthus will work with I caught and the Oxford University to develop VTP-500 through phase 2 tests, as they noted in a statement. If good results are recorded, the association will continue to develop a reserve of 100,000 doses that could be quickly deployed in the event of an outbreak.
“With this project, we will advance scientific understanding of the coronavirus family as a whole and, at the same time, strengthen humanity’s ability to respond to an epidemic threat”
“Coronaviruses are one of the threats of most urgent infectious diseases facing the world, so it is vital that we continue to develop medical defenses against this particularly deadly disease. With this project, we will advance the scientific understanding of the coronavirus family as a whole and, at the same time, strengthen humanity’s ability to respond to an ever-present epidemic threat,” said the Dr. Richard Hatchettexecutive director of CEPI.
VTP-500 has already been tested in a Phase 1 study in Great Britain and Saudi Arabia, and an extension is underway to test the candidate in the United Kingdom for older adults. Another proof of its importance is that this program received the designation of priority medicationsor PRIME, from the European Medicines Agency (EMA) earlier this month.
These new funds will be in addition to those previously committed to the University of Oxford to develop a MERS candidate. A coming association since 2016when Vaccitech and its universal flu vaccine candidate emerged.
2023-12-24 23:00:00
#Barinthus #receives #investment #million #euros
